Giulio Superti-Furga

Giulio Superti-Furga
Giulio Superti-Furga, Ph.D. in 2011
Born	(1962-05-17) 17 May 1962 Milan, Italy
Nationality	Italian
Fields	Molecular Biology, Medical Systems Biology, Pharmacology
Institutions	CeMM

Giulio Superti-Furga (born 17 May 1962 in Milan) is an Italian molecular and systems biologist based in Vienna, Austria. He is the Scientific Director of CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, and Professor of Medical Systems Biology at the Medical University of Vienna Medical University of Vienna.

Amongst his most significant scientific achievements to date are the elucidation of basic regulatory mechanisms of tyrosine kinases in human cancers and the discovery of fundamental organization principles of the proteome of higher organisms, which is one of the most highly cited papers in the field. His work has directly contributed to a systems-level understanding of pathogen infections in host cells and of the mechanism of action of specific drugs. He is an advocate for the adoption of systems biology approaches for medicine and in particular for drug discovery and aims to bridge basic research and the clinical world.

Giulio Superti-Furga has published some 166 manuscripts listed in Pubmed^[1] and some 254 publications in ISI Web of Science^[2] that have been collectively cited > 20,000 times (excl. self), reflected by an h-index of 60. The paper "Functional organization of the yeast proteome by systematic analysis of protein complexes" by Gavin, AC*, 36 authors, Superti-Furga G* (* shared correspondence), Nature 2002, Jan 10; 414:141-147 has been cited > 4,600 times (Google Scholar) or > 2,600 times according to ISI Web of Science and is a Faculty of 1000 All Time Top 10 paper in biology. His current work focuses on protein complexes, molecular networks and drugs relevant for leukemia and host immune defense mechanisms against pathogens.

CV

Giulio Superti-Furga was educated at the German School of Milan (DSM) in Milan, Italy. He performed his undergraduate and graduate studies in Molecular Biology at the University of Zurich, at Genentech Inc. in San Francisco and at the Research Institute of Molecular Pathology (IMP) in Vienna. Giulio Superti-Furga was a post-doctoral fellow at the European Molecular Biology Laboratory (EMBL) in Heidelberg and became Team Leader in 1995. From 1997 to 2000 he served as Guest Professor of Molecular Biology at the University of Bologna, Italy. In 2000, he co-founded the biotech company Cellzome Inc. and served as Scientific Director.^[3] Since 2005 he has been Scientific Director of CeMM; the Research Center for Molecular Medicine of the Austrian Academy of Sciences. From 2005 to 2014 Giulio Superti-Furga was a Visiting Professor of Molecular Pharmacology at the Medical University of Vienna, where he was recently appointed as Professor of Medical Systems Biology as of 2015. Furthermore, he is serving on the Scientific Advisory Board of several institutions. Giulio Superti-Furga chairs the board of the EMBL Alumni Association,^[4] which has ~2,500 members. In 2009, he was awarded the Knight Officer Order of Merit of the Republic of Italy for his contributions to science. In 2010 he co-founded the biotechnology company Haplogen GmbH in Vienna, a CeMM spin-off focused on haploid genetics.^[5] Haplogen Genomics, a former daughter company of Haplogen that in 2013 together with CeMM released the world's largest collection of engineered human haploid knockout cell lines for biomedical discovery doi:10.1038/nmeth.2609,^[6] in 2015 became part of the Horizon group as Horizon Genomics GmbH.^[7] In February 2013 the eight nominees of the Board of the University of Vienna elected Giulio Superti-Furga as ninth member to serve for a five-year term.^[8] He is married and has two children.

Personal Genome

Giulio Superti-Furga's personal genome sequence PGA1 is publicly available on Genom Austria, the Austrian Personal Genome Project initiative within the Global Network of Personal Genome Projects, PersonalGenomes.org.

Honors

2004–2010: Faculty of 1000 Biology, Member, Genomics Section
2005: European Molecular Biology Organization (EMBO), Member
2007: Austrian Academy of Sciences, Corresponding Member
2008: German Academy of Sciences Leopoldina, Member^[9]
2008: Dance Your PhD Contest,^[10] Science Magazine, Winner Professor Category
2009: Order of Merit of the Republic of Italy, Knight Officer
2009: Austrian Society of Allergology and Immunology, Karl Landsteiner Prize^[11]
2009: European Research Council, Advanced Investigator Grant
2010: European Academy of Cancer Sciences, Fellow
2010: Austrian Academy of Sciences, Full Member^[12]
2011: Austrian Scientist of the Year^[13]
2011: Prize of the City of Vienna for Natural Sciences^[14]
2013–2018: Board of the University of Vienna, elected member
2014: Academia Europaea, Member^[15]

Bibliography

(selected)

Gavin, A.C. et al.: Functional organization of the yeast proteome by systematic analysis of protein complexes. 'Nature. 2002; 415:141–147, doi:10.1038/415141a.
Pluk, H. et al.: Autoinhibition of c-Abl. Cell. 2002; 108:247–259, doi:10.1016/S0092-8674(02)00623-2.
Hantschel, O. et al.: A Myristoyl / Phosphotyrosine Switch Regulates c-Abl. Cell. 2003; 112:845–857, doi:10.1016/S0092-8674(03)00191-0.
Bouwmeester, T. et al.: A physical and functional map of the human TNF-/NF-B signal transduction pathway. Nature Cell Biology. 2004; 6:97–105, doi:10.1038/ncb1086.
Gavin, A.C. et al.: Proteome survey reveals modularity of the yeast cell machinery. Nature. 2006; 440(7084):631-6, doi:10.1038/nature04532.
Burckstummer, T. et al.: An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells. Nat. Methods. 2006; 3(12):1013-9, doi:10.1038/nmeth968.
Rix, U. et al.: Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal novel kinase and non-kinase targets. Blood. 2007; 110(12):4055-63, doi:10.1182/blood-2007-07-102061.
Henney, A. and Superti-Furga, G.: A network solution. Nature. 2008; 455(7214):730-1, doi:10.1038/455730a.
Bürckstümmer, T. et al.: An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol. 2009; 10(3):266-72, doi:10.1038/ni.1702.
Brehme, M., Hantschel, O. et al.: Charting the molecular network of the drug target Bcr-Abl. Proc Natl Acad Sci U S A. 2009; 106(18):7414–9, doi:10.1073/pnas.0900653106.
Dixit, E. et al.: Peroxisomes are signaling platforms for antiviral innate immunity. Cell. 2010; 141(4):668-81, doi:10.1016/j.cell.2010.04.018.
Rix, U. et al.: A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells. Leukemia. 2010, 24: 44–50, doi:10.1038/leu.2009.228.
Pichlmair, A. et al.: IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Nat Immunol. 2011, 12(7):624-30, doi:10.1038/ni.2048.
Grebien, F. et al.: Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell. 2011, 147(2):306-19, doi:10.1016/j.cell.2011.08.046.
Winter, G.E. et al.: Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nat Chem Biol. 2012; 8(1):905-12, doi:10.1038/nchembio.1085.
Varjosalo, M. et al.: Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS. Nat. Methods. 2013; 10(4): 307-14, doi:10.1038/nmeth.2400.
Huber, K.V. et al.: Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy. Nature. 2014; 508(7495):222-7, doi:10.1038/nature13194.
Winter, G.E. et al.: The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Nat Chem Biol. 2014; 10(09):768-73, doi:10.1038/nchembio.1590.
Rebsamen, M. et al.: SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature. 2015; 519(7544):477-81, doi:10.1038/nature14107.

References

External links

Authority control	VIAF: 220277600 ORCID: 0000-0002-0570-1768 SUDOC: 116241926 ResearcherID: F-4755-2015

This article is issued from Wikipedia - version of the Wednesday, July 01, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.